Revvity, Inc.
Financials
Valuation Metrics
Revvity, Inc.'s Market Cap is $16.37B. At end of 2025 it was $10.95B. Ranked #668 of 3,121 in US market (top 21%), #461 of 1,658 on NYSE (top 28%), #45 of 205 in Health Care Equipment & Services (top 22%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $16.37B | US#668/3,121 Sec#45/205 |
| Revenue | $2.91B | US#1,218/3,121 Sec#74/205 |
| Net Income | $238M | US#1,205/3,121 Sec#58/205 |
| Total Assets | $12.05B | US#885/3,121 Sec#42/205 |
| Net Assets | $7.23B | US#546/3,121 Sec#31/205 |
| Employees | 11,000 | US#815/3,121 Sec#62/205 |
| Value | ||
| P/E | 68.90x | US#2,019/3,121 Sec#105/205 |
| P/B | 2.26x | US#1,405/3,121 Sec#67/205 |
| P/S | 5.62x | US#2,386/3,121 Sec#154/205 |
| EV/EBITDA | 24.36x | US#2,089/3,121 Sec#103/205 |
| FCF Yield | 3.42% | US#1,747/3,121 Sec#97/205 |
| Profitability | ||
| ROE | 3.29% | US#1,949/3,121 Sec#100/205 |
| ROA | 1.97% | US#1,655/3,121 Sec#102/205 |
| Op. Margin | 12.32% | US#1,414/3,121 Sec#60/205 |
| Revenue Growth | 4.05% | US#1,902/3,121 Sec#142/205 |
| Earnings Growth | -17.07% | US#1,525/3,121 Sec#79/205 |
| Financial Health | ||
| Debt Ratio | 66.64% | US#734/3,121 Sec#79/205 |
| Total Debt | $3.34B | US#897/3,121 Sec#41/205 |
| FCF | $559M | US#849/3,121 Sec#47/205 |
| Cash | $1.02B | US#676/3,121 Sec#38/205 |
| Current Ratio | 1.80x | US#1,383/3,121 Sec#119/205 |
| Net Debt/EBITDA | 3.02x | US#1,613/3,121 Sec#99/205 |
| Dividend | ||
| Div. Yield | 0.19% | US#1,649/3,121 Sec#52/205 |
| Div. Growth | 3.21% | US#957/3,121 Sec#35/205 |
| Performance | ||
| 1Y Return | 72.06% | US#346/3,121 Sec#34/205 |
| 1M Return | 28.98% | US#44/3,121 Sec#10/205 |
| From 52W High | -1.87% | US#103/3,121 Sec#17/205 |
| 1Y MDD | -30.14% | US#1,433/3,121 Sec#62/205 |
| Trading | ||
| Volume | 2,325,406 shares | US#738/3,121 Sec#38/205 |
| Trading Value | $342M | US#268/3,121 Sec#18/205 |
| Per Share | ||
| EPS | $2.13 | US#1,295/3,121 Sec#64/205 |
| BPS | $64.80 | US#272/3,121 Sec#21/205 |
Company Info
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.